Picture your Future. Save for it by earning 1.5% on a 1-year Term Deposit Account! Learn more.

Liontrust Insights: The bull and bear cases for the stock market

By James Dowey, Chief Investment Officer at Liontrust Asset Management

When analysing the impact of the Covid-19 pandemic on the stock market, by far the most significant bear case to worry about logically follows from the widely reported and influential recent Imperial College study of the virus.

The team at Imperial believes we may need to keep applying severe social distancing measures until a vaccine becomes available because the virus is likely to bounce back whenever we lift the restrictions again. The problem is that a vaccine is perhaps 18 months away so this could cause a depression.

Right now, demand is collapsing across much of the global economy because it must. It is inhumane not to shut down the economy to suppress the virus. The immediate job for economic policy is an unusual one: rather than stimulate a recovery now, it must build a bridge to a recovery once the threat of the virus has been removed.

As such, evaluating the economy as it pertains to the stock market is a bit different this time around compared with previous recessions. The bridge needs to be built well and hopefully will not be required to span too great a distance.

As ever, it is essential to the bull case that central banks fulfil their key role of lender of last resort to financial markets under extraordinary stress. Encouragingly, they are moving through the gears extremely quickly, benefiting from the experience gained and tools built during the Global Financial Crisis (GFC) in 2008/09. They have more to do but appear up to the challenge.

Fiscal policies have rightly focused on helping businesses and households maintain critical levels of cash flow and incentivising businesses to keep employees in jobs where possible. In this way, the government can hopefully preserve the supply capacity of the economy until the demand recovery is possible.

While dramatic, as long as the recovery is not too distant, this appears doable. Say the level of GDP were to fall a huge 30% during social distancing, then fully supporting cash flows would cost the government about 2.5% of annual GDP per month.

This would obviously be an unthinkable burn rate in normal times but would coincide now with substantial QE programmes and would compare with an overall rise in G7 countries’ average government debt to GDP ratios of 33% due to the GFC.

However, it is my strongly held view that the absolutely pivotal policy measure upon which the bull case for stocks rests lies in breaking the bleak logic of the Imperial study. Put simply, the mass scaling up of production of virus tests and personal protective equipment (PPE) for everyone – the whole population – over the coming weeks can prevent a depression. This might seem banal by comparison with the development of the vaccine that will hopefully ultimately eradicate the virus or even monetary and fiscal fireworks. But the other key to a successful and timely recovery is building a basic infrastructure for an economy that can live with Covid-19 until the vaccine arrives, whilst running at a good level of activity, successfully suppressing the virus and protecting the vulnerable.

Close to daily home testing of almost everyone who hasn’t had the virus will enable the rapid identification of local outbreaks. These can then be combated efficiently by contact tracing and rapid localised social distancing measures.

Technology can help with this approach in the form of smart phone apps that enable live mapping of the virus, which is already being used in some Asian countries. Pervasive antibody testing will tell us everyone who has had the virus and who is thus now at much lower risk, at least temporarily. 

PPE for everyone will feel a bit unusual at first but will help to reduce transmission sufficiently to give people the confidence to go back to work. It will help protect the vulnerable and enable others to look after them without harming the vulnerable.

To achieve all this, the degree of scaling up required resembles past wartime efforts to reorient swathes of production facilities towards delivering supplies. This will not be possible without governments’ orchestration and commitment to purchasing the enormous quantities needed. With social distancing and macroeconomic support policies in place, it is the policy we need to see next.

If this does happen, today’s stock valuations, sitting at around the 10th to 20th percentiles across major developed markets, are attractive. If not, it is worth noting that valuations are still some significant way above the trough of 2009 and the outlook could be worse than then.     

Preventing the bear case is absolutely not beyond our capacity.


Liontrust Key risks and Disclaimers


Past performance is not a guide to future performance. Do remember that the value of an investment and the income generated from them can fall as well as rise and is not guaranteed, therefore, you may not get back the amount originally invested and potentially risk total loss of capital. The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term. Investment in the GF High Yield Bond Fund involves foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. The value of fixed income securities will fall if the issuer is unable to repay its debt or has its credit rating reduced. Generally, the higher the perceived credit risk of the issuer, the higher the rate of interest. Bond markets may be subject to reduced liquidity. The Fund may invest in emerging markets/soft currencies and in financial derivative instruments, both of which may have the effect of increasing volatility.

Issued by Liontrust Fund Partners LLP (2 Savoy Court, London WC2R 0EZ), authorised and regulated in the UK by the Financial Conduct Authority (FRN 518165) to undertake regulated investment business. This document should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. It contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, faxed, reproduced, divulged or distributed, in whole or in part, without the express written consent of Liontrust. Always research your own investments and (if you are not a professional or a financial adviser) consult suitability with a regulated financial adviser before investing. 


MeDirect Disclaimers

This information has been accurately reproduced, as received from Liontrust Fund Partners LLP. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment and may be deducted from the invested amount therefore lowering the size of your investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest should always be based upon the details contained in the Prospectus and Key Investor Information Document (KIID), which may be obtained from MeDirect Bank (Malta) plc.

 

Join MeDirect today to access the tools you need to put your money to work on your own terms.

Latest news articles

Experience better Banking

The sooner you start managing your money, your way, using the best-in-class tools, the sooner you’ll see results. 


Sign up and open your account for free, within minutes.

MeDirect_Multi-Devices-cards

You are leaving medirect.com.mt

Please be aware that the external site policies, or those of another MeDirect website, may differ from this website’s terms and conditions and privacy policy. The next website will open in a new browser window or tab.

 

Note: MeDirect is not responsible for any content on third party sites, nor does a link suggest endorsement of those sites and/or their content.

Login

We strive to ensure a streamlined account opening process, via a structured and clear set of requirements and personalised assistance during the initial communication stages. If you are interested in opening a corporate account with MeDirect, please complete an Account Opening Information Questionnaire and send it to corporate@medirect.com.mt.

For a comprehensive list of documentation required to open a corporate account please contact us by email at corporate@medirect.com.mt or by phone on (+356) 2557 4444.